Innate Pharma SA Adjustments For Unrealised Foreign Exchange Losses Gains
Innate Pharma SA (IPHA) reported Adjustments For Unrealised Foreign Exchange Losses Gains of EUR 1.36 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Income Statement › Other Income
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains · last filed 2026-04-01
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 6 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month |
|---|---|---|
| 2025-12-31 | 1.36M EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | 1.35M EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | -885.00K EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | -524.00K EUR 6-K · filed 2025-09-17 | |
| 2023-12-31 | 544.00K EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 288.00K EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | -912.00K EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | -1.33M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | -1.14M EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | -443.00K EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | 1.26M EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | -48.00K EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | -280.00K EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | -1.34M EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 3.38M EUR 20-F · filed 2020-04-24 |